Skip to main content
ABSTRACT & COMMENTARY

Induction Therapy for HIV/AIDS-Related Disseminated Histoplasmosis with Single High-Dose Liposomal Amphotericin B

In a Phase II randomized clinical trial involving 118 participants in Brazil with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related disseminated histoplasmosis, induction therapy with single high-dose (10 mg/kg) liposomal amphotericin B was safe and non-inferior as compared with standard dose (3 mg/kg) liposomal amphotericin B given once daily for 14 days.